Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs. The recent expiration of patents of some anti-TNFα biologics (such as infliximab and adalimumab) facilitated the development of biosimilar...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2024-07-01
|
| Seri Bilgileri: | Frontiers in Pharmacology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1424606/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|